Less Than One in 20 Eligible Adults Receives Lung Cancer Screening
FRIDAY, Nov. 20, 2020 -- Less than one in 20 eligible U.S. adults receives annual lung cancer screening (LCS) using low-dose computed tomography scans, with wide geographic variance in screening rates, according to a study published online Nov. 12 in the Journal of the National Cancer Institute.
Stacey A. Fedewa, Ph.D., from the American Cancer Society in Atlanta, and colleagues estimated the LCS rate and growth at the national and state level between 2016 and 2018 using data from the American College of Radiology Lung Cancer Screening Registry.
The researchers found that nationally, the screening rate was steady between 2016 (3.3 percent) and 2017 (3.4 percent) and increased to 5 percent in 2018 (2018 versus 2016 screening rate ratio, 1.52). Several Southern states with a high lung cancer burden (e.g., Mississippi, West Virginia, Arkansas) had relatively low screening rates in 2018 (less than 4 percent) among eligible adults compared with Northeastern states with lower lung cancer burden but the highest screening rates (e.g., Massachusetts, Vermont, New Hampshire: screening rate ratio range, 12.8 to 15.2 percent). Kentucky, which had the nation's highest lung cancer mortality rate, also had one of the highest screening rates (13.7 percent).
"Deliberate effort from various stakeholders such as policy makers, cancer control, health systems, and providers [is] needed to boost lung cancer screening rates among eligible adults with a heavy smoking history, a group facing multiple barriers to lung cancer screening and cancer care," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: November 2020
Read this next
MONDAY, Nov. 23, 2020 -- Social needs are associated with lower health-related quality of life (HRQOL) among African American cancer survivors, according to a study published...
FRIDAY, Nov. 20, 2020 -- Lung cancer survival has increased to 22.6 percent nationally, and people of color face worse outcomes than White Americans, according to a report from...
THURSDAY, Nov. 19, 2020 -- Among patients with previously untreated advanced ALK-positive non-small cell lung cancer (NSCLC), progression-free survival is significantly longer for...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.